Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465515 · ClinicalTrials.gov registry record · Phase 4
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 9,463
- Enrollment target
NCT02465515: Completed Phase 4 study, sponsored by GlaxoSmithKline.
NCT02465515 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 9,463 participants, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1730% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02465515, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9,463 participants
- Enrollment target
Study Summary
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Primary Outcome
Time to MACE defined as the time to first occurrence of Cardiovascular Endpoint Committee (CEC)-adjudicated MACE (CV death, myocardial infarction \[MI\] or stroke) was analyzed using a Cox Proportional Hazards regression model with treatment group as the only covariate. The incidence rate per 100 person years (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% confidence interval. First event person-years=(cumulative total time to first event
Interventions
- BIOLOGICAL Albiglutide 30 mg
- BIOLOGICAL Albiglutide 50 mg
- BIOLOGICAL Albiglutide matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,463 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2018-03-14 |
| Phase | Phase 4 |
What the finished NCT02465515 record still lists
NCT02465515 is an interventional study that assigns participants to a tested intervention. Its 9,463 participants enrollment target places it among the larger protocols in the corpus, above the 517-participant average among 9,235 other Phase 4 trials with a reported enrollment target (1730% higher).
The record links to 0 conditions, and to 3 interventions - of which Albiglutide 30 mg is the first listed.
NCT02465515 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02465515 about?
NCT02465515 is a clinical study titled "Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus". Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used...
What is the current status of trial NCT02465515?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9,463 participants. The study started on 2015-07-01. Estimated completion is 2018-03-14.
What interventions are being tested in trial NCT02465515?
The interventions under investigation include: Albiglutide 30 mg (BIOLOGICAL), Albiglutide 50 mg (BIOLOGICAL), Albiglutide matching placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02465515?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02465515's enrollment target sits among peer trials
9,463 9th of 2000 higher than 1,992 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI